SCHEMBL13808145

SCHEMBL13808145

CCCNC(=O)c1ccc2c(c1)N=C(c1ccc(F)cc1)c1ccccc1S2

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 9/20 0.75
CNR2 P34972 2/20 0.71
TP53 P04637 4/20 0.68
SMN1; SMN2 Q16637 2/20 0.59
NPSR1 Q6W5P4 2/20 0.56
PLA2G1B P04054 1/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
PAX8 Q06710 1/20 0.55
ATG4B Q9Y4P1 1/20 0.55
POLB P06746 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
LMNA P02545 1/20 0.54
GAA P10253 1/20 0.54
ALDH1A1 P00352 1/20 0.54
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5057332 0.95 CNR1 (0.83) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL14043590 0.92 CNR1 (0.77) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL13807819 0.91 CNR1 (0.67) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL13808230 0.91 CNR1 (0.65) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL13807936 0.91 CNR1 (0.71) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL13808136 0.90 CNR1 (0.69) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL5057738 0.90 CNR1 (0.75) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL13808137 0.90 CNR1 (0.91) CNR1CNR2TP53SMN1; SMN2NPSR1
SCHEMBL5062615 0.89 CNR1 (0.72) CNR1CNR2TP53SMN1; SMN2MAPT
SCHEMBL5054066 0.89 CNR1 (0.67) CNR1CNR2TP53SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009075691-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2009-06-18 WO disclosed
WO-2008118141-A2 USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY ACADIA PHARMACEUTICALS INC. (US) 2008-10-02 WO disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed
US-20070105819-A1 CB-1 modulating compounds and their use ACADIA PHARMACEUTICALS, INC. 2007-05-10 US disclosed
US-20070105819-A1 CB-1 modulating compounds and their use ACADIA PHARMACEUTICALS, INC. 2007-05-10 US disclosed
WO-2007047737-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105819-A1 CB-1 modulating compounds and their use CNR1, CNR2, FAAH CNR1 1/4885CNR2 2/4885TP53 4870/4885
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH CNR1 1/4885CNR2 2/4885TP53 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.